Recurrent pneumonia among Japanese adults: Disease burden and risk factors

BMC Pulmonary Medicine

Volumn 17, Issue 1, 2017, Pages

  Ishifuji, Tomoko ^a   Sando, Eiichiro ^a,b   Kaneko, Norihiro ^b   Suzuki, Motoi ^a   Kilgore, Paul E ^c   Ariyoshi, Koya ^a   Morimoto, Konosuke ^a   Hosokawa, Naoto ^b   Yaegashi, Makito ^b   Aoshima, Masahiro ^b   Abe, Masahiko ^d   Wakabayashi, Takao ^d   Katsurada, Naoko ^b   Nakashima, Kei ^b   Otsuka, Yoshihito ^b   Shibui, Kaori ^b   Suzuki, Daisuke ^b   Tanaka, Kenzo ^b   Tochitani, Kentaro ^b   Chikamori, Masayuki ^e   Hamashige, Naohisa ^e   Ishida, Masayuki ^e   Nakaoka, Hiroshi ^e   Aso, Norichika ^f   Ito, Hiroyuki ^f   Matsuki, Kei ^f   Tsuchihashi, Yoshiko ^f   Dhoubhadel, Bhim G ^a   Furumoto, Akitsugu ^a   Hamaguchi, Sugihiro ^a,e   Katoh, Shungo ^a,e   Kakiuchi, Satoshi ^a   Kitashoji, Emi ^a   Shimazaki, Takaharu ^a   Takaki, Masahiro ^a   Watanabe, Kiwao ^a   Yoshida, Lay Myint ^a   more..

^a NAGASAKI UNIVERSITY   (Japan)

^b KAMEDA MEDICAL CENTER   (Japan)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Ebetsu City Hospital   (Japan)

^e Chikamori Hospital   (Japan)

^f Department of Neurosurgery   (Japan)

Author keywords

Community acquired pneumonia; Elderly; Epidemiology; Recurrent pneumonia

Indexed keywords

CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYPNOTIC AGENT; HYPNOTIC SEDATIVE AGENT;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BACTERIUM DETECTION; BODY MASS; CHRONIC LUNG DISEASE; COMMUNITY HOSPITAL; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG USE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HEALTH CARE ASSOCIATED PNEUMONIA; HUMAN; INCIDENCE; JAPANESE (PEOPLE); LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OBSERVATIONAL STUDY; PNEUMONIA; PROGNOSIS; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; RECURRENT DISEASE; RECURRENT PNEUMONIA; RISK FACTOR; RISK REDUCTION; SPUTUM CULTURE; SURVIVAL; TREATMENT DURATION; UNDERWEIGHT; COMMUNITY-ACQUIRED INFECTIONS; COST OF ILLNESS; JAPAN; MICROBIOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PNEUMONIA, BACTERIAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM; SURVIVAL ANALYSIS; URINE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; COMMUNITY-ACQUIRED INFECTIONS; COMORBIDITY; COST OF ILLNESS; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; INCIDENCE; JAPAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECURRENCE; RISK FACTORS; SPUTUM; SURVIVAL ANALYSIS; URINE; YOUNG ADULT;

EID: 85009250887     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/s12890-016-0359-1     Document Type: Article

References (43)

1. Population survey. Department Minister's Secretariat. Ministry of Health, Labor and Welfare Japan. 2011. http://www.e-stat.go.jp/SG1/estat/GL08020101.do?_toGL08020101_&tstatCode=000001028897&requestSender=dsearch. Accessed 9 Jul 2014.
2. Jackson ML, Neuzil KM, Thompson WW, Shay DK, Yu O, Hanson CA, Jackson LA. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis. 2004;39:1642-50.
3. Morimoto K, Suzuki M, Ishifuji T, Yaegashi M, Asoh N, Hamashige N, Abe M, Aoshima M, Ariyoshi K, Wakabayashi T, Hosokawa N, Kaneko N, Katsurada N, Nakashima K, Otsuka Y, Sando E, Shibui K, Suzuki D, Tanaka K, Tochitani K, Chikamori M, Ishida M, Nakaoka H, Ito H, Matsuki K, Tsuchihashi Y, Dhoubhadel BG, Furumoto A, Hamaguchi S, Katoh S, et al. The burden and etiology of community-onset pneumonia in the aging Japanese population: a multicenter prospective study. PLoS One. 2015;10:e0122247.
4. Winterbauer RH, Bedon GA, Ball WCJ. Recurrent pneumonia. Ann Intern Med. 1969;70:689-700.
5. Hedlund JU, Ortqvist AB, Kalin M, Scalia-Tomba G, Giesecke J. Risk of pneumonia in patients previously treated in hospital for pneumonia. Lancet. 1992;340:396-7.
6. Garcia-Vidal C, Carratalà J, Fernández-Sabé N, Dorca J, Verdaguer R, Manresa F, Gudiol F. Aetiology of, and risk factors for, recurrent community-acquired pneumonia. Clin Microbiol Infect. 2009;15:1033-8.
7. Dang TT, Eurich DT, Weir DL, Marrie TJ, Majumdar SR. Rates and risk factors for recurrent pneumonia in patients hospitalized with community-acquired pneumonia: population-based prospective cohort study with 5 years of follow-up. Clin Infect Dis. 2014;59:74-80.
8. Ekdahl K, Braconier JH, Rollof J. Recurrent pneumonia: a review of 90 adult patients. Scand J Infect Dis. 1992;24:71-6.
9. Hedlund J, Kalin M, Ortqvist A. Recurrence of pneumonia in middle-aged and elderly adults after hospital-treated pneumonia: aetiology and predisposing conditions. Scand J Infect Dis. 1997;29:387-92.
10. Crim C, Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Willits LR, Yates JC, Vestbo J. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009;34:641-7.
11. Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: A systematic review and meta-analysis. PLoS One. 2015;10:e0128004.
12. Ohkubo T, Chapman N, Neal B, Woodward M, Omae T, Chalmers J. Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. Am J Respir Crit Care Med. 2004;169:1041-5.
13. LaCroix AZ, Lipson S, Miles TP, White L. Prospective study of pneumonia hospitalizations and mortality of U.S. Older people: the role of chronic conditions, health behaviors, and nutritional status. Public Health Rep. 1988;104:350-60.
14. Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013;68:1057-65.
15. Mortensen EM, Pugh MJ, Copeland LA, Restrepo MI, Cornell JE, Anzueto A, Pugh JA. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J. 2008;31:611-7.
16. Gau J-T, Acharya U, Khan S, Heh V, Mody L, Kao T-C. Pharmacotherapy and the risk for community-acquired pneumonia. BMC Geriatr. 2010;10:45.
17. Reza Shariatzadeh M, Huang JQ, Marrie TJ. Differences in the features of aspiration pneumonia according to site of acquisition: community or continuing care facility. J Am Geriatr Soc. 2006;54:296-302.
18. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med Amer Thorac Soc. 2005;171:388-416.
19. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG. Infectious diseases society of america/american thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2:S27-72.
20. Neill AM, Martin IR, Weir R, Anderson R, Chereshsky A, Epton MJ, Jackson R, Schousboe M, Frampton C, Hutton S, Chambers ST, Town GI. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax. 1996;51:1010-6.
21. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377-82.
22. Dahabreh IJ, Kent DM. Index event bias as an explanation for the paradoxes of recurrence risk research. JAMA. 2011;305:822-3.
23. Taylor JK, Fleming GB, Singanayagam A, Hill AT, Chalmers JD. Risk factors for aspiration in community-acquired pneumonia: analysis of a hospitalized UK cohort. Am J Med. 2013;126:995-1001.
24. Almirall J, Bolíbar I, Serra-Prat M, Roig J, Hospital I, Carandell E, Agustí M, Ayuso P, Estela A, Torres A. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J. 2008;31:1274-84.
25. Obiora E, Hubbard R, Sanders RD, Myles PR. The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort. Thorax. 2013;68:163-70.
26. Dublin S, Ros L, Walker M. Use of opioids or benzodiazepines and risk of pneumonia in olders: a population-based case-control study. J Am Geriatr Soc. 2011;59:1899-907.
27. Iqbal U, Syed-Abdul S, Nguyen PA, Jian W-S, Li Y-CJ. The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort. Thorax. 2013;68:591-2.
28. Vergis EN, Brennen C, Wagener M, Muder RR. Pneumonia in long-term care: a prospective case-control study of risk factors and impact on survival. Arch Intern Med. 2001;161:2378-81.
29. El Solh AA, Brewer T, Okada M, Bashir O, Gough M. Indicators of recurrent hospitalization for pneumonia in the elderly. J Am Geriatr Soc. 2004;52:2010-15.
30. Tagaya H. Pharmacotherapy of insomnia in clinical medicine. Folia Pharmacol Jpn. 2007;129:42-6.
31. International Narcotics Control Board. Report of the International Narcotics Control Board for 2010. New York: United Nations; 2011.
32. Eurich DT, Lee C, Marrie TJ, Majumdar SR. Inhaled corticosteroids and risk of recurrent pneumonia: a population-based, nested case-control study. Clin Infect Dis. 2013;57:1138-44.
33. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;3:CD010115.
34. Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007;4:CD006829.
35. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2016. http://www.goldcopd.org/. Accessed 6 Jun 2016.
36. Iannella H, Luna C, Waterer G. Inhaled corticosteroids and the increased risk of pneumonia: what's new? a 2015 updated review. Ther Adv Respir Dis. 2016;10(3):235-55.
37. Sekizawa K, Matsui T, Nakagawa T, Nakayama K, Sasaki H. ACE inhibitors and pneumonia. Lancet. 1998;352:1069.
38. Eurich DT, Sadowski CA, Simpson SH, Marrie TJ, Majumdar SR. Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs. Am J Med. 2010;123:47-53.
39. Myles PR, Hubbard RB, Gibson JE, Pogson Z, Smith CJP, McKeever TM. The impact of statins, ACE inhibitors and gastric acid suppressants on pneumonia mortality in a UK general practice population cohort. Pharmacoepidemiol Drug Saf. 2009;18:697-703.
40. Beck JM, Young VB, Huffnagle GB. The microbiome of the lung. Transl Res. 2012;160:258-66.
41. Parkins MD, Gregson DB, Pitout JDD, Ross T, Laupland KB. Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection. Infection. 2010;38:25-32.
42. El-Solh AA, Pietrantoni C, Bhat A, Aquilina AT, Okada M, Grover V, Gifford N. Microbiology of severe aspiration pneumonia in institutionalized elderly. Am J Respir Crit Care Med. 2003;167:1650-4.
43. Falguera M, Carratalà J, Ruiz-Gonzalez A, Garcia-Vidal C, Gazquez I, Dorca J, Gudiol F, Porcel JM. Risk factors and outcome of community-acquired pneumonia due to Gram-negative bacilli. Respirology. 2009;14:105-11.